Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3-ITD) mutations occur in about 25% of all acute myeloid leukemia (AML) patients and confer a poor prognosis. FLT3 inhibitors have been developed to treat patients with FLT3-mutated AML and have shown promise, though the acquisition o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shuangshuang, Edwards, Holly, Wang, Deying, Liu, Shuang, Qiao, Xinan, Carter, Jenna, Wang, Yue, Taub, Jeffrey W., Wang, Guan, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455003/
https://www.ncbi.nlm.nih.gov/pubmed/36078163
http://dx.doi.org/10.3390/cells11172752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455003/
https://www.ncbi.nlm.nih.gov/pubmed/36078163
http://dx.doi.org/10.3390/cells11172752

Ejemplares similares